Nana Agyemang, Kimberly K Scarsi, Paxton Baker, Laura M Smeaton, Anthony T Podany, Maxine Olefsky, Elizabeth Woolley, Elizabeth Barr, Michelle Pham, Sajeeda Mawlana, Khuanchai Supparatpinyo, Sivaporn Gatechompol, Emilia M Jalil, Luis Gadama, Sharlaa Badal-Faesen, Marije Van Schalkwyk, Cecelia Kayama, Pablo F Belaunzaran-Zamudio, Catherine Godfrey, Susan E Cohn, Rosie Mngqibisa, David W Haas
OBJECTIVE: In AIDS Clinical Trials Group study A5375, a pharmacokinetic trial of levonorgestrel emergency contraception, double-dose levonorgestrel (3 mg, versus standard dose 1.5 mg) offset the induction effects of efavirenz or rifampin on plasma levonorgestrel exposure over 8 h post-dose (AUC0-8h). We characterized the pharmacogenetics of these interactions. METHODS: Cisgender women receiving efavirenz- or dolutegravir-based HIV therapy, or on isoniazid-rifampin for tuberculosis, were followed after a single oral dose of levonorgestrel...
June 12, 2023: Pharmacogenetics and Genomics